TR004 (Treg immunotherapy) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 1 |
96. Crohn disease
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03185000 (ClinicalTrials.gov) | August 8, 2022 | 13/4/2017 | Treg Immunotherapy in Crohn's Disease | A First in Human Feasibility Study of T Regulatory Cells (TR004) for Inflammatory Bowel Disease Using (ex Vivo) Treg Expansion | Crohn Disease | Drug: TR004 (Treg immunotherapy) | King's College London | Guy's and St Thomas' NHS Foundation Trust;Medical Research Council;St. George's Hospital, London;Miltenyi biotech | Recruiting | 18 Years | 80 Years | All | 4 | Phase 1 | United Kingdom |